New Delhi, June 22, 2016
– The IPM grew at 10% in May 2016
– The IPM was valued at Rs.106, 134 crores and the retail sector was valued at Rs.89,071 crores as of MAT May 2016
– 3.4% IPM affected due to the recent ban imposed by the GOI on 344 drugs; acute therapies form 81% of the total banned portfolio
– In the Banned Portfolio analysis, Respiratory constitutes 43% of the overall value; however all other therapeutic areas see a massive dip since February 2016
– In terms of companies, Top 10 companies affected by the ban contribute to 62% of the overall value of the banned portfolio
– Pfizer though contributing highest to banned portfolio reflects positive growth since last three months
IMS Health Market Reflection Report – May 2016
Corporate Comm India (CCI Newswire)
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…